UCB

Pamish has signed a 6-year supply contract with Belgian pharmaceutical company UCB to provide mPEG-20k, a raw material for UCB's autoimmune disease drug Cimzia. The contract is effective from January 23, 2017, with automatic annual renewals thereafter.

Pamishield (파미셀) signed a 6-year contract with Belgian pharmaceutical company UCB to supply mPEG-20k, a raw material for the autoimmune disease drug Cimzia. The contract is effective from January 23, 2017, with automatic one-year renewals thereafter.